Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Metastatic renal cell carcinoma, outcomes, papillary, response rate, survival, targeted therapy, PHASE-II, OPEN-LABEL, SUNITINIB, SURVIVAL, TRIAL, EVEROLIMUS, NONCLEAR, EFFICACY, TYPE-1, MULTICENTER, Antineoplastic Agents, Carcinoma, Renal Cell, Clinical Trials as Topic, Disease-Free Survival, Female, Humans, Kidney Neoplasms, Male, Molecular Targeted Therapy, Neoplasm Metastasis, Prognosis, Standard of Care, Survival Analysis, Treatment Outcome, 0601 Biochemistry and Cell Biology, 1112 Oncology and Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.